Identifying population-based eGFR distributions may help to identify patients at risk for developing chronic kidney disease earlier, according to study data published in Kidney International. More ...

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.

Aumolertinib and osimertinib showed similar efficacy and safety in treating EGFR-mutant NSCLC, with no significant differences in progression-free survival or overall survival. The study involved 202 ...

FDA approved a simplified, once-monthly dosing schedule for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) when used in combination with Lazcluze (lazertinib) as a first-line treatment for ...

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...

Medically reviewed by Robert Burakoff, MD Key Takeaways Stage 1 CKD often doesn't cause noticeable symptoms but requires measures to preserve kidney function.Managing high blood pressure and diabetes ...

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...